Exploring Knee Osteoarthritis Relief with Growth Hormone Injections

Suspended Phase 2 NCT06354023

Study Description

Osteoarthritis sufferers dealing with knee pain and mobility issues may find potential relief through a clinical trial exploring the use of growth hormone injections. This treatment targets to stimulate the regrowth of articular chondrocytes - the essential cells of knee cartilage. As these cells rebuild the cartilage, it could reduce pain, enhance knee function, and possibly delay the requirement for knee replacement surgery. Throughout the trial, subjects will undergo a series of growth hormone injections directly into the knee joint, one per week over a six-week period. To support the treatment's effectiveness, subjects must also participate in supplementary at-home exercises. The use of crutches is advised if necessary for mobility during the trial phase. Progress will be closely monitored with X-ray imaging and regular follow-ups at specific intervals post-treatment, including assessments at 8 weeks, 6 months, and a year after the initial injection. Additionally, subjects will provide feedback on their condition before and after the treatment via surveys. The trial seeks to answer critical questions about the efficacy of growth hormone injections in improving cartilage health and overall joint function in knee osteoarthritis.

Study Details

Registry ID:
NCT06354023
Conditions:
Osteoarthritis, Knee
Phase:
Phase 2
Target Enrollment:
23 participants
Start Date:
Age Range:
18–72 years
Healthy Volunteers:
No

Study Locations (1 site)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →